董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bryce Carmine | 男 | Non-Executive Director | -- | 9.31万美元 | 未持股 | 2023-10-26 |
| John Friend | 男 | Chief Executive Officer and Interim Chairman | -- | 62.87万美元 | 未持股 | 2023-10-26 |
| Ebru Davidson | 女 | Non-Executive Director | -- | 未披露 | 未持股 | 2023-10-26 |
| Steven Coffey | 男 | Non-Executive Director | -- | 9.31万美元 | 未持股 | 2023-10-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Friend | 男 | Chief Executive Officer and Interim Chairman | -- | 62.87万美元 | 未持股 | 2023-10-26 |
| Karen Krumeich | 女 | Chief Financial Officer | -- | 26.64万美元 | 未持股 | 2023-10-26 |
| Anna Sandham | 女 | Company Secretary | -- | 未披露 | 未持股 | 2023-10-26 |
董事简历
中英对照 | 中文 | 英文- Bryce Carmine
-
Bryce Carmine，他担任 Eli Lilly & Co.的职务36年，并退任Eli Lilly & Co的执行副总裁和Lilly Bio-Medicines的总裁。在此之前他领导全球药品销售和营销并且是公司的执行委员会的成员。他曾担任一系列的产品开发的投资组合的领导职务，当时他被任命为Eli Lilly全球医药产品开发总裁负责其所有治疗领域整个后期阶段管道的发展。在Lilly的职业生涯期间，他担任许多国家领导职务，包括Eli Lilly Japan总裁，澳大利亚/新西兰事总经理，韩国首尔 Lilly合资企业总经理。
Bryce Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he led the Global Pharmaceutical Sales and Marketing and was a member of the Company's Executive Committee. Bryce previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly. During his career with Lilly, Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea. Bryce is currently Chairman and CEO of HaemaLogiX Pty Ltd, a Sydney based privately owned biotech. - Bryce Carmine，他担任 Eli Lilly & Co.的职务36年，并退任Eli Lilly & Co的执行副总裁和Lilly Bio-Medicines的总裁。在此之前他领导全球药品销售和营销并且是公司的执行委员会的成员。他曾担任一系列的产品开发的投资组合的领导职务，当时他被任命为Eli Lilly全球医药产品开发总裁负责其所有治疗领域整个后期阶段管道的发展。在Lilly的职业生涯期间，他担任许多国家领导职务，包括Eli Lilly Japan总裁，澳大利亚/新西兰事总经理，韩国首尔 Lilly合资企业总经理。
- Bryce Carmine spent 36 years working for Eli Lilly & Co. and retired as Executive Vice President for Eli Lilly & Co, and President, Lilly Bio-Medicines. Prior to this he led the Global Pharmaceutical Sales and Marketing and was a member of the Company's Executive Committee. Bryce previously held a series of product development portfolio leadership roles culminating when he was named President, Global Pharmaceutical Product Development, with responsibility for the entire late-phase pipeline development across all therapeutic areas for Eli Lilly. During his career with Lilly, Bryce held several country leadership positions including President Eli Lilly Japan, Managing Dir. Australia/NZ & General Manager of a JV for Lilly in Seoul, Korea. Bryce is currently Chairman and CEO of HaemaLogiX Pty Ltd, a Sydney based privately owned biotech.
- John Friend
-
John Friend是一位经验丰富的肿瘤学和血液学药物开发人员，他热衷于改善癌症患者的生活。在超过25年的职业生涯中，Friend博士在从早期临床研究到医学事务的广泛治疗领域工作。他以前担任Helsinn Therapeutics美国业务部门的医疗和科学事务高级副总裁，最近在Cellectar生物科学公司担任首席医疗官，该公司是一家临床阶段的美国专注于肿瘤学的生物技术公司。Friend博士在罗格斯大学（UMDNJ-Robert Wood Johnson）获得医学学位，他还拥有南方卫理公会大学的化学学士学位。
John Friend,is a highly experienced physician executive who has previously worked with companies ranging from start-up biotechnology companies to multinational pharmaceutical companies. Over the past 15 years, his focus has been in the oncology and hematology therapeutic space. Dr. Friend is a US-trained physician who practiced medicine in North Carolina before transitioning to drug development. Before joining Kazia Therapeutics, he was Chief Medical Officer and member of the executive management team at Cellectar Biosciences, Inc, a US publicly traded biopharmaceutical company. - John Friend是一位经验丰富的肿瘤学和血液学药物开发人员，他热衷于改善癌症患者的生活。在超过25年的职业生涯中，Friend博士在从早期临床研究到医学事务的广泛治疗领域工作。他以前担任Helsinn Therapeutics美国业务部门的医疗和科学事务高级副总裁，最近在Cellectar生物科学公司担任首席医疗官，该公司是一家临床阶段的美国专注于肿瘤学的生物技术公司。Friend博士在罗格斯大学（UMDNJ-Robert Wood Johnson）获得医学学位，他还拥有南方卫理公会大学的化学学士学位。
- John Friend,is a highly experienced physician executive who has previously worked with companies ranging from start-up biotechnology companies to multinational pharmaceutical companies. Over the past 15 years, his focus has been in the oncology and hematology therapeutic space. Dr. Friend is a US-trained physician who practiced medicine in North Carolina before transitioning to drug development. Before joining Kazia Therapeutics, he was Chief Medical Officer and member of the executive management team at Cellectar Biosciences, Inc, a US publicly traded biopharmaceutical company.
- Ebru Davidson
-
Ebru Davidson是一位经验丰富的公司律师，目前是QBiotics Group Limited的总法律顾问，QBiotics Group Limited是一家未上市的澳大利亚生命科学上市公司。在此之前，戴维森是美国国家律师事务所Thomson Geer Lawyers的合伙人，在股权资本市场、私人和公开并购、公司交易和公司治理方面拥有超过14年的经验。戴维森还在为上市和非上市实体提供合规和监管方面的咨询方面拥有丰富的经验，她与澳大利亚证券和投资委员会以及澳大利亚证券交易所密切合作。
Ebru Davidson,is a highly experienced corporate lawyer and is currently the General Counsel for QBiotics Group Limited, an unlisted public Australian life sciences company. Prior to this, Ms Davidson was a partner at national law firm Thomson Geer Lawyers and has over 14 years' experience in equity capital markets, private and public mergers and acquisitions, corporate transactions and corporate governance. Ms Davidson also has extensive experience in advising listed and unlisted entities on compliance and regulatory matters working closely with the Australian Securities and Investment Commission and Australian Securities Exchange. - Ebru Davidson是一位经验丰富的公司律师，目前是QBiotics Group Limited的总法律顾问，QBiotics Group Limited是一家未上市的澳大利亚生命科学上市公司。在此之前，戴维森是美国国家律师事务所Thomson Geer Lawyers的合伙人，在股权资本市场、私人和公开并购、公司交易和公司治理方面拥有超过14年的经验。戴维森还在为上市和非上市实体提供合规和监管方面的咨询方面拥有丰富的经验，她与澳大利亚证券和投资委员会以及澳大利亚证券交易所密切合作。
- Ebru Davidson,is a highly experienced corporate lawyer and is currently the General Counsel for QBiotics Group Limited, an unlisted public Australian life sciences company. Prior to this, Ms Davidson was a partner at national law firm Thomson Geer Lawyers and has over 14 years' experience in equity capital markets, private and public mergers and acquisitions, corporate transactions and corporate governance. Ms Davidson also has extensive experience in advising listed and unlisted entities on compliance and regulatory matters working closely with the Australian Securities and Investment Commission and Australian Securities Exchange.
- Steven Coffey
-
Steven Coffey， 他是注册会计师，自从1983年毕业于新南威尔士大学（University of New South Wales）后一直在事务所工作。从1993年起，他担任注册律师事务所Watkins Coffey Martin的合伙人。他是一家注册公司的审计员，为喜多大型私人公司和非盈利实体提供审计服务。他先前担任一家澳大利亚上市公司的董事会成员，目前是私人家族基金会的董事会成员。
Steven Coffey is a Chartered Accountant and registered company auditor and has over 35 years experience in the accounting and finance industry. He has been a partner with the chartered accounting firm Watkins Coffey Martin which recently merged with Charternet Chartered Accountants and Steven is a consultant to that group. Steven sits on the board of a number of large private family companies and audits a number of large private companies and not-for-profit entities. - Steven Coffey， 他是注册会计师，自从1983年毕业于新南威尔士大学（University of New South Wales）后一直在事务所工作。从1993年起，他担任注册律师事务所Watkins Coffey Martin的合伙人。他是一家注册公司的审计员，为喜多大型私人公司和非盈利实体提供审计服务。他先前担任一家澳大利亚上市公司的董事会成员，目前是私人家族基金会的董事会成员。
- Steven Coffey is a Chartered Accountant and registered company auditor and has over 35 years experience in the accounting and finance industry. He has been a partner with the chartered accounting firm Watkins Coffey Martin which recently merged with Charternet Chartered Accountants and Steven is a consultant to that group. Steven sits on the board of a number of large private family companies and audits a number of large private companies and not-for-profit entities.
高管简历
中英对照 | 中文 | 英文- John Friend
John Friend是一位经验丰富的肿瘤学和血液学药物开发人员，他热衷于改善癌症患者的生活。在超过25年的职业生涯中，Friend博士在从早期临床研究到医学事务的广泛治疗领域工作。他以前担任Helsinn Therapeutics美国业务部门的医疗和科学事务高级副总裁，最近在Cellectar生物科学公司担任首席医疗官，该公司是一家临床阶段的美国专注于肿瘤学的生物技术公司。Friend博士在罗格斯大学（UMDNJ-Robert Wood Johnson）获得医学学位，他还拥有南方卫理公会大学的化学学士学位。
John Friend,is a highly experienced physician executive who has previously worked with companies ranging from start-up biotechnology companies to multinational pharmaceutical companies. Over the past 15 years, his focus has been in the oncology and hematology therapeutic space. Dr. Friend is a US-trained physician who practiced medicine in North Carolina before transitioning to drug development. Before joining Kazia Therapeutics, he was Chief Medical Officer and member of the executive management team at Cellectar Biosciences, Inc, a US publicly traded biopharmaceutical company.- John Friend是一位经验丰富的肿瘤学和血液学药物开发人员，他热衷于改善癌症患者的生活。在超过25年的职业生涯中，Friend博士在从早期临床研究到医学事务的广泛治疗领域工作。他以前担任Helsinn Therapeutics美国业务部门的医疗和科学事务高级副总裁，最近在Cellectar生物科学公司担任首席医疗官，该公司是一家临床阶段的美国专注于肿瘤学的生物技术公司。Friend博士在罗格斯大学（UMDNJ-Robert Wood Johnson）获得医学学位，他还拥有南方卫理公会大学的化学学士学位。
- John Friend,is a highly experienced physician executive who has previously worked with companies ranging from start-up biotechnology companies to multinational pharmaceutical companies. Over the past 15 years, his focus has been in the oncology and hematology therapeutic space. Dr. Friend is a US-trained physician who practiced medicine in North Carolina before transitioning to drug development. Before joining Kazia Therapeutics, he was Chief Medical Officer and member of the executive management team at Cellectar Biosciences, Inc, a US publicly traded biopharmaceutical company.
- Karen Krumeich
Karen Krumeich在公司融资方面拥有30多年的经验，几乎完全专注于生命科学领域。她一直负责推动众多私营和公共生物技术公司的发展。过去20年的大部分时间里，她都在处于成长期的公立和私立生物技术公司担任首席财务官，包括Soligenix和Theravectys公司。除了会计资格外，Karen还是一名合格的药剂师，毕业于托莱多大学药学院。
Karen Krumeich has more than thirty years of experience in corporate finance, focused almost entirely on the life sciences sector. She has been responsible for driving the growth of numerous private and public biotech companies. For most of the last twenty years, she served as Chief Financial Officer to growth-stage biotech companies, both public and private, including Soligenix, Inc, and Theravectys, Inc. In addition to her accounting qualifications, Karen is a qualified pharmacist and a graduate of the University of Toledo School of Pharmacy.- Karen Krumeich在公司融资方面拥有30多年的经验，几乎完全专注于生命科学领域。她一直负责推动众多私营和公共生物技术公司的发展。过去20年的大部分时间里，她都在处于成长期的公立和私立生物技术公司担任首席财务官，包括Soligenix和Theravectys公司。除了会计资格外，Karen还是一名合格的药剂师，毕业于托莱多大学药学院。
- Karen Krumeich has more than thirty years of experience in corporate finance, focused almost entirely on the life sciences sector. She has been responsible for driving the growth of numerous private and public biotech companies. For most of the last twenty years, she served as Chief Financial Officer to growth-stage biotech companies, both public and private, including Soligenix, Inc, and Theravectys, Inc. In addition to her accounting qualifications, Karen is a qualified pharmacist and a graduate of the University of Toledo School of Pharmacy.
- Anna Sandham
Anna Sandham拥有超过25年的公司秘书和治理专业经验，曾在ASX上市公司和私有公司工作。安娜受雇于公司事务有限公司（领展集团的一部分）。在2012年加入Company Matters之前，Anna是AMP金融服务公司的公司秘书，在此之前，她是澳洲西太平洋银行集团的公司秘书，在那里她还领导了英国电信金融集团的秘书处职能。安娜还在私营和公共部门担任公司秘书职务，包括NRMA有限公司。Anna拥有经济学学士学位（悉尼大学）和应用公司治理研究生文凭（澳大利亚治理研究所）。她是一名特许治理专业人员、澳大利亚治理研究所研究员和立法审查委员会成员。
Anna Sandham,has more than 25 years' experience as a company secretary and governance professional, working with ASX listed and privately owned companies. Anna is employed by Company Matters Pty Ltd (part of the Link Group). Prior to joining Company Matters in 2012, Anna was a Company Secretary at AMP Financial Services and prior to that was Company Secretary at Westpac Banking Corporation where she also led the secretariat function for the BT Financial Group. Anna has also held company secretarial roles within the private and public sectors, including NRMA Limited. Anna holds a Bachelor of Economics (University of Sydney) and a Graduate Diploma of Applied Corporate Governance (Governance Institute of Australia). She is a Chartered Governance Professional, a Fellow of the Governance Institute of Australia and a member of its Legislative Review Committee.- Anna Sandham拥有超过25年的公司秘书和治理专业经验，曾在ASX上市公司和私有公司工作。安娜受雇于公司事务有限公司（领展集团的一部分）。在2012年加入Company Matters之前，Anna是AMP金融服务公司的公司秘书，在此之前，她是澳洲西太平洋银行集团的公司秘书，在那里她还领导了英国电信金融集团的秘书处职能。安娜还在私营和公共部门担任公司秘书职务，包括NRMA有限公司。Anna拥有经济学学士学位（悉尼大学）和应用公司治理研究生文凭（澳大利亚治理研究所）。她是一名特许治理专业人员、澳大利亚治理研究所研究员和立法审查委员会成员。
- Anna Sandham,has more than 25 years' experience as a company secretary and governance professional, working with ASX listed and privately owned companies. Anna is employed by Company Matters Pty Ltd (part of the Link Group). Prior to joining Company Matters in 2012, Anna was a Company Secretary at AMP Financial Services and prior to that was Company Secretary at Westpac Banking Corporation where she also led the secretariat function for the BT Financial Group. Anna has also held company secretarial roles within the private and public sectors, including NRMA Limited. Anna holds a Bachelor of Economics (University of Sydney) and a Graduate Diploma of Applied Corporate Governance (Governance Institute of Australia). She is a Chartered Governance Professional, a Fellow of the Governance Institute of Australia and a member of its Legislative Review Committee.